First Medical Oncology Clinic, Saint-Savvas Anticancer Hospital, Athens, Greece.
Department of Oncology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
Expert Rev Anticancer Ther. 2021 Jun;21(6):591-604. doi: 10.1080/14737140.2021.1880327. Epub 2021 Mar 12.
: Breast sarcomas (BS) are uncommon and often present both diagnostic and therapeutic challenges. Historically, radical surgery has been the mainstay of treatment for localized breast sarcomas. On the other hand, in advanced disease, since they are a heterogeneous group of neoplasms consisting of several different subtypes including angiosarcoma, phyllodes tumor, and pleomorphic undifferentiated sarcoma, there is a lack of proven specific therapy. As a result, their treatment is based on the soft tissue sarcoma (STS) paradigm, whereas histotype-tailored approaches apply to specific subtypes like dermatofibrosarcoma protuberans. To date, advanced stages constitute an incurable form of disease and chemotherapy remains the cornerstone of treatment with the aim of palliation of symptoms and increase in survival.: In this manuscript, we review the clinicopathologic characteristics of the most common subtypes of BS, as well as the current treatment landscape of BS, with a particular focus on opportunities and challenges provided by new targeted molecules and immunotherapy.: The treatment approach of advanced BS is based on the pathologic subtype. A true breakthrough has still to be obtained, as the development of new agents in BS suffers from the same weaknesses as in other STS.
: 乳腺肉瘤（BS）较为罕见，常同时存在诊断和治疗方面的挑战。历史上，局部乳腺肉瘤的主要治疗方法是根治性手术。另一方面，对于晚期疾病，由于它们是由多种不同亚型组成的异质性肿瘤群，包括血管肉瘤、叶状肿瘤和多形性未分化肉瘤，缺乏经过验证的特定治疗方法。因此，它们的治疗基于软组织肉瘤（STS）的范例，而针对特定亚型（如隆突性皮肤纤维肉瘤）的组织类型定制的方法适用。迄今为止，晚期疾病构成了无法治愈的疾病形式，化疗仍然是治疗的基石，旨在缓解症状和提高生存率。: 在本文中，我们回顾了最常见的 BS 亚型的临床病理特征，以及 BS 的当前治疗现状，特别关注新的靶向分子和免疫疗法提供的机会和挑战。: 晚期 BS 的治疗方法基于病理亚型。真正的突破仍有待实现，因为 BS 中新型药物的开发与其他 STS 一样存在弱点。
